Corpus ID: 237504444

ASGARD: A Single-cell Guided pipeline to Aid Repurposing of Drugs

  title={ASGARD: A Single-cell Guided pipeline to Aid Repurposing of Drugs},
  author={Bing He and Lana X. Garmire},
  • Bing He, L. Garmire
  • Published 2021
  • Medicine, Biology
  • ArXiv
Intercellular heterogeneity is a major obstacle to successful personalized medicine. Single-cell RNA sequencing (scRNA-seq) technology has enabled in-depth analysis of intercellular heterogeneity in various diseases. However, its full potentials for personalized medicine are yet to be reached. Towards this, we propose A Single-cell Guided pipeline to Aid Repurposing of Drugs (ASGARD). ASGARD can repurpose single drugs for each cell cluster and for multiple cell clusters at individual patient… Expand

Tables from this paper


Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data
The utility of bioinformatics for identifying drugs than can be repurposed for potentially treating COVID-19 patients is demonstrated. Expand
Using single-cell multiple omics approaches to resolve tumor heterogeneity
Continuing advancements in single-cell technology and computational deconvolution of data will be critical for reconstructing patient specific intra-tumour features and developing more personalized cancer treatments. Expand
Comprehensive integration of single cell data
This work presents a strategy for comprehensive integration of single cell data, including the assembly of harmonized references, and the transfer of information across datasets, and demonstrates how anchoring can harmonize in-situ gene expression and scRNA-seq datasets. Expand
Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing
A proof-of-concept trial using the TCGA breast cancer dataset demonstrates the application of Dr Insight for a comprehensive analysis, from redirection of drug therapies, to a systematic construction of disease-specific drug-target networks. Expand
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
A comprehensive review of public data sets related to HCC is provided and how emerging artificial intelligence methods can be applied to identify new targets and drugs as well as to guide therapeutic choices for improved HCC treatment is discussed. Expand
COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas
It is identified that different peripheral immune subtype changes were associated with distinct clinical features including age, sex, severity, and disease stages of COVID-19, and SARS-CoV-2 RNAs were found in diverse epithelial and immune cell types, accompanied by dramatic transcriptomic changes within viral positive cells. Expand
The Drug Repurposing Hub: a next-generation drug library and information resource
This work hand-curated a collection of 4,707 compounds, experimentally confirmed their identities, and annotated them with literature-reported targets, to assemble a comprehensive library of drugs that have reached the clinic and established a blueprint for others to easily assemble such a repurposing library. Expand
Identification of Repurposal Drugs and Adverse Drug Reactions for Various Courses of Coronavirus Disease 2019 (COVID-19) Based on Single-cell RNA Sequencing Data
This work employed a systematic approach to mine candidates from U.S. FDA approved drugs and pre-clinical small-molecule compounds by integrating the gene expression perturbation data by chemicals from the Library of Integrated Network-Based Cellular Signatures (LINCS) project with publically available single-cell RNA sequencing dataset from mild and severe COVID-19 patients. Expand
Single-cell analysis tools for drug discovery and development
These tools for single-cell genomic, transcriptomic and multiplex proteomic analyses for drug discovery and development, particularly in the field of oncology, are reviewed. Expand
Targeting the cell cycle in breast cancer: towards the next phase
The latest generation of cell cycle targeting anti-cancer agents for breast cancer, including approved CDK4/6 inhibitors, and investigational TTK and PLK4 inhibitors that are currently in clinical trials are discussed. Expand